Mon Feb 02 15:00:00 UTC 2026: ### Pfizer Attracts Investor Interest Amidst Mixed Analyst Ratings
The Story:
Jones Financial Companies Lllp increased its stake in Pfizer Inc. by 9.9% in the third quarter, acquiring an additional 297,458 shares. Several other institutional investors, including Curio Wealth LLC, Harbor Asset Planning Inc., and Grey Fox Wealth Advisors LLC, also increased or initiated positions in Pfizer during the second and third quarters of 2025. This activity occurs against a backdrop of varied analyst ratings, ranging from “sector outperform” to “strong sell,” and a current average rating of “Hold” with an average price target of $28.06.
Key Points:
- Jones Financial Companies Lllp increased its Pfizer holdings by 9.9% in Q3 2025.
- Curio Wealth LLC increased its stake by 36,600% in Q2 2025, though the absolute value remains small.
- Pfizer reported Q3 2025 earnings of $0.87 per share, exceeding estimates by $0.08.
- Analysts’ ratings vary widely, from “Strong Buy” to “Sell,” with an average rating of “Hold”.
- Pfizer declared a quarterly dividend of $0.43 per share, payable on March 6th, 2026, representing a 6.5% yield.
Key Takeaways:
- Despite mixed analyst sentiment, some institutional investors are increasing their positions in Pfizer, potentially indicating confidence in the company’s long-term prospects.
- Pfizer’s recent earnings exceeded expectations, suggesting a positive performance trend.
- The high dividend yield could be attracting income-focused investors.
- The variance in analyst ratings underscores the uncertainty surrounding Pfizer’s future performance, likely influenced by factors such as drug pipeline development and market competition.
First Piper 